Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, has entered into an exclusive worldwide license and collaboration agreement with Achillion Pharmaceuticals to develop and commercialize one or more of Achillion’s lead hepatitis C virus (HCV) assets, which include ACH-3102, ACH-3422 and sovaprevir.    The companies will work to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. Achillion’s ACH-3102, an NS5A inhibitor current...